328 W. Claiborne St.
P.O. Box 964
Monroeville, Alabama 36460
(251) 575-4203
Alzheimers Disease and other Cognitive Disorders
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Poor Sleep May Heighten Alzheimer's RiskWhat Caregivers Should Know About Alzheimer'sHealth Tip: Recognize Symptoms of Traumatic Brain InjuryHealth Tip: Next Steps After Being Diagnosed With Alzheimer'sEyes May Be Window Into Future Memory LossCardiorespiratory Fitness, White Matter Integrity Tied to CognitionMolecular Markers May ID Alzheimer's Before Clinical OnsetIn Alzheimer's, BACE1 Inhibition May Reverse Amyloid DepositionTherapy Reverses Alzheimer's Brain Plaque Buildup -- in MiceLow Serum Sodium Linked to Cognitive Decline in Older MenPositive Age Beliefs May Protect Seniors Against DementiaYour Attitude About Aging Might Affect Odds for DementiaWhat Works Best to Keep Drivers With Dementia Off the RoadDeep Brain Stimulation May Be Promising Alzheimer's TreatmentEarly Alzheimer's Tied to Rest-Activity Rhythm FragmentationBrain 'Pacemaker' Might Help Slow Alzheimer'sSolanezumab Doesn't Affect Cognitive Decline in Alzheimer'sAnother Alzheimer's Drug Fails: What Makes This Disease So Tough to Fight?Seizure Drug May Help Ease Symptoms of Major Form of DementiaHealth Tip: Disaster Preparedness For People With Alzheimer'sFalls More Common in Elderly With Cognitive ImpairmentConcussion May Not Be Needed to Bring on CTE Brain DiseaseAlzheimer's Disease Variants Linked to Brain AmyloidosisIdalopirdine May Not Improve Cognition in Mild Alzheimer'sHealth Tip: Alzheimer's and the HolidaysNo Magic Bullet for Preventing Late-Life DementiaDementia May Be More Common in Rural AreasThere's Still No Proven Way to Prevent Alzheimer'sHealth Tip: Make Your Home Safer For People With Alzheimer'sAlzheimer's Cases to Double by 2060: ReportGene Discovery May Help Fight Alzheimer'sCould New 'Brain Training' Program Help Prevent Dementia?Millions Could Miss Out on a Potential Alzheimer's BreakthroughSleep Apnea May Boost Alzheimer's RiskNew Finding Hints at Clue to DementiaResilient Brain Connections May Help Against Alzheimer'sAmerica's Dementia Caregivers Cite Stresses, RewardsHealth Tip: Identifying Vascular DementiaOne Type of Dementia Is Especially CostlyA More Accurate Predictor for Alzheimer's?Failing Sense of Smell Tied to Dementia RiskIs Dementia Declining Among Older Americans?Intracranial Pressure Monitoring No Benefit in Pediatric TBIGender-Specific High-Risk 'Window' Seen in Alzheimer'sWomen at Risk for Alzheimer's Face Critical 10-Year Window, Study SaysDo Fewer Nightly Dreams Mean Higher Dementia Risk in Seniors?Dementia Care: A Huge Financial Burden for U.S. FamiliesPopular Heartburn Drugs Don't Raise Risk of Alzheimer's: StudyFamilies Shoulder Majority of Costs Related to Dementia CareMidlife Vascular Risk Factors Tied to Increased Risk of Dementia
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Idalopirdine May Not Improve Cognition in Mild Alzheimer's

HealthDay News
Updated: Jan 9th 2018

new article illustration

TUESDAY, Jan. 9, 2018 (HealthDay News) -- The use of idalopirdine does not improve cognition versus placebo over 24 weeks of treatment for patients with mild-to-moderate Alzheimer's disease (AD), according to research published in the Jan. 9 issue of the Journal of the American Medical Association.

Alireza Atri, M.D., Ph.D., from the California Pacific Medical Center in San Francisco, and colleagues conducted three randomized 24-week clinical trials that included 2,525 patients aged 50 years or older with mild-to-moderate AD to examine whether idalopirdine is effective for symptomatic treatment of mild-to-moderate AD.

The researchers found that the mean change in the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) was 0.37, 0.61, and 0.41 for the 60- and 30-mg idalopirdine groups and the placebo group, respectively (adjusted mean difference versus placebo: 0.05 [95 percent confidence interval (CI), −0.88 to 0.98] and 0.33 [95 percent CI, −0.59 to 1.26], respectively), in study 1. In study 2, the mean change in ADAS-Cog total score was 1.01, 0.53, and 0.56 for the 30- and 10-mg groups, and placebo, respectively (adjusted mean difference versus placebo, 0.63 [95 percent CI, −0.38 to 1.65] for the 30-mg group). The mean change in ADAS-Cog total score in study 3 was 0.38 and 0.82 for the 60-mg and placebo groups, respectively (adjusted mean difference, −0.55 [95 percent CI, −1.45 to 0.36]).

"These findings do not support the use of idalopirdine for the treatment of AD," the authors write.

Several authors disclosed financial ties to medical device and pharmaceutical companies, including H. Lundbeck A/S, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net